Affordable Access

deepdyve-link
Publisher Website

Nanotechnology in pulmonary medicine.

Authors
  • Doroudian, Mohammad1
  • O' Neill, Andrew2
  • Mac Loughlin, Ronan3
  • Prina-Mello, Adriele4
  • Volkov, Yuri5
  • Donnelly, Seamas C6
  • 1 Department of Medicine, Tallaght University Hospital & Trinity College Dublin, Ireland; Department of Cell and Molecular Sciences, Faculty of Biological Sciences, Kharazmi University, Tehran, Iran. , (Ireland)
  • 2 Department of Medicine, Tallaght University Hospital & Trinity College Dublin, Ireland. , (Ireland)
  • 3 Aerogen, IDA Business Park, Dangan, Galway, Ireland; School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons, Dublin, Ireland; School of Pharmacy and Pharmaceutical Sciences, Trinity College, Dublin, Ireland. , (Ireland)
  • 4 Laboratory for Biological Characterization of Advanced Materials (LBCAM), Department of Medicine, Trinity College Dublin, Ireland; Nanomedicine Group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Ireland; CRANN Institute and AMBER Centre, Trinity College Dublin, Ireland. , (Ireland)
  • 5 Laboratory for Biological Characterization of Advanced Materials (LBCAM), Department of Medicine, Trinity College Dublin, Ireland; Nanomedicine Group, Trinity Translational Medicine Institute (TTMI), Trinity College Dublin, Ireland; CRANN Institute and AMBER Centre, Trinity College Dublin, Ireland; Department of Histology, Cytology and Embryology, First Moscow State Sechenov Medical University, Moscow, Russian Federation. , (Ireland)
  • 6 Department of Medicine, Tallaght University Hospital & Trinity College Dublin, Ireland. Electronic address: [email protected] , (Ireland)
Type
Published Article
Journal
Current opinion in pharmacology
Publication Date
Dec 17, 2020
Volume
56
Pages
85–92
Identifiers
DOI: 10.1016/j.coph.2020.11.002
PMID: 33341460
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Nanotechnology in medicine-nanomedicine-is extensively employed to diagnose, treat, and prevent pulmonary diseases. Over the last few years, this brave new world has made remarkable progress, offering opportunities to address historical clinical challenges in pulmonary diseases including multidrug resistance, adverse side effects of conventional therapeutic agents, novel imaging, and earlier disease detection. Nanomedicine is also being applied to tackle the new emerging infectious diseases, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), influenza A virus subtype H1N1 (A/H1N1), and more recently, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this review we provide both a historical overview of the application of nanomedicine to respiratory diseases and more recent cutting-edge approaches such as nanoparticle-mediated combination therapies, novel double-targeted nondrug delivery system for targeting, stimuli-responsive nanoparticles, and theranostic imaging in the diagnosis and treatment of pulmonary diseases. Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Report this publication

Statistics

Seen <100 times